trending Market Intelligence /marketintelligence/en/news-insights/trending/hhwmo3uxkpvlob2dz1idew2 content esgSubNav
In This List

ProQR Therapeutics stock price jumps on news of drug success in clinical trial

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


ProQR Therapeutics stock price jumps on news of drug success in clinical trial

ProQR Therapeutics N.V.'s stock price was up more than 66% on Sept. 5 after the Cambridge, Mass.-based biotechnology company said its medicine was effective in treating a rare inherited eye disease.

The company's stock price was trading at $13.20 per share in pre-market trading Sept. 5, 2018, up 66.04% from the previous day's close.

An interim analysis of the company's early stage clinical trial of QR-110 showed the therapy demonstrated rapid and sustained improvement in vision in patients with Leber's congenital amaurosis 10, or LCA 10, due to a specific gene mutation.

QR-110 was well-tolerated in patients with no serious adverse events in the phase 1/2 trial of the therapy. Improvement in visual function was observed as early as two months after treatment and was maximal and stable by three months and thereafter, the company said in a statement.

ProQR said that LCA10, which typically leads to childhood blindness, has no available treatment options.

ProQR said it will stop enrollment in the current trial and progress to a phase 2/3 trial, which will be called Illuminate and is expected to start in the first half of 2019.